Biotech Values

[mcbio]

Re: ARNA

ARNA submits Lorcaserin NDA:

I won't touch ARNA in front of FDA approval, but if lorcaserin does in fact get approved (they met the FDA efficacy threshold) and the stock does not increase too much, I think ARNA could be interesting. Most seem to count the drug out commercially because of the efficacy, but the drug did show strong benefit in a portion of patients and, presumably more importantly, most expect the drug to be combined with phentermine in a real-world setting. That could presumably further boost efficacy, although the question remains whether or not FDA will hold up approval because ARNA did not test lorcaserin in combo w/phentermine in its trials.